Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
about
Clinical relevance of botulinum toxin immunogenicityComparison and overview of currently available neurotoxinsBotulinum toxin type A products are not interchangeable: a review of the evidence.Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?Botulinum toxin: bioweapon & magic drugProfile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasmA new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteinsBotulinum toxin type A treatment to the upper face: retrospective analysis of daily practicePractical guidance for CD management involving treatment of botulinum toxin: a consensus statement.Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins--a single cohort 4-year follow-up study.Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia.New trends in the science of botulinum toxin-A as applied in dystonia.Advances in the use of botulinum neurotoxins in facial esthetics.Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence.Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disordersPharmacokinetics and pharmacodynamics of incobotulinumtoxinA influencing the clinical efficacy in post-stroke spasticity.A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystoniaIncobotulinumtoxinA: A Review in Upper Limb Spasticity.Functional influence of botulinum neurotoxin type A treatment (Xeomin®) of multifocal upper and lower limb spasticity on chronic hemiparetic gait'Similar to' is not 'identical with', and 'identical with' is not 'the same as'.Neurologic uses of botulinum neurotoxin type A.Response to Commentary by W. Jost on: Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products.Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.Consistent biochemical data are essential for comparability of botulinum toxin type A products.Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke.Botulinum Toxin in Aesthetic Medicine: Myths and Realities.Treatment of compensatory hyperhidrosis after sympathectomy with botulinum toxin and anticholinergics.Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.Early use of Xeomin neurotoxin for local anti-spasticity therapy for pes equines after acquired brain injury (ABI).Report of Allergic Reaction After Application of Botulinum Toxin.
P2860
Q26824771-FC8DC71A-6F37-4DD7-894D-41E1E0911D55Q27030752-79A2B7C4-7A2E-428C-B157-22CFFB37B948Q34352934-DBDE71DC-A6C1-4DB0-A1A6-61C9071E7CD4Q34443530-DB26D519-777D-4A7A-A4F8-2FC7EDED6B7AQ34530009-3DC69F7C-94A5-4B7F-8E75-B45FE6CADD39Q35050218-B4DEC691-D299-4B0E-9C38-9769CF9144E0Q35681898-F3518204-4940-4013-864D-317F79B84A2CQ36085760-FD89C77B-8301-4C93-BD99-E66F3A2552F6Q36171693-BE4923B9-BB63-45F6-875B-AB97E8432235Q36254051-53E0C52F-F7CC-4811-9284-EA91B9C2BDBFQ36650003-D6C74B00-0FE9-4B37-8DCB-75A026DD850AQ36694302-586E5CDD-AE77-4408-A0C8-2C637CD689FFQ36847246-4169872B-A481-4697-9A65-E379A6B04514Q37129916-E186437D-808E-49E7-8E9D-B2B737A726FFQ37829742-CFB07C53-A637-4592-AFF7-4238EE88C71EQ37987557-55B71411-227B-4961-B44D-3190CE55CFDCQ38098126-EB64E494-6AC6-436B-B70F-2D446DA70536Q38432422-B784C956-8448-4593-B908-119FDA3AA1C0Q38735879-D08C9AF5-7B35-4A08-8DD6-C84AFADE4FBBQ38749925-7E492EC6-BC59-49D6-98B3-BEE37410A2C1Q38929059-1DA438F2-AA66-452E-BEC8-033787015BF7Q41456082-ABD93CDC-562D-4B9A-8DE6-F9B23705DA14Q41879288-037CBC73-6ECC-4758-B295-C62E941EE6BEQ42086848-087A821B-8519-4D60-973B-98BC6AEC1E34Q42378237-2CAAFE35-F16A-49D7-B77D-4D9FE3BBB4CBQ43185582-07ED07C3-05FD-4DED-8C9F-FBF49B545FECQ43237101-DE552FC1-5D4A-4442-8362-6F3684B00585Q44502462-0A35E1E1-C0F5-4A70-BB39-8D70EC4C2E42Q47671772-C7C09A35-627E-4DFC-A6B1-3C07F24330ACQ47735763-34E51662-C9C4-428D-8C17-27BDC0C2CD4AQ48791267-0454D303-43E0-4276-BCD5-24E0F8D76F68Q48870387-A6099771-EB3C-4E19-A122-B06E2BF85D45Q53471137-B3BA79C3-BA76-4CE8-9327-0AE995A8C99C
P2860
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
@ast
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
@en
type
label
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
@ast
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
@en
prefLabel
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
@ast
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
@en
P2093
P1433
P1476
Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.
@en
P2093
Jörg Blümel
Susanne Grafe
Wolfgang H Jost
P2860
P304
P356
10.2165/00003495-200767050-00003
P577
2007-01-01T00:00:00Z
P6179
1039632984